Alport syndrome medical therapy

Revision as of 20:58, 31 October 2013 by Rim Halaby (talk | contribs) (→‎Renal transplantation)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Alport syndrome Microchapters


Patient Information


Historical Perspective



Differentiating Alport syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alport syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Alport syndrome medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alport syndrome medical therapy

CDC on Alport syndrome medical therapy

Alport syndrome medical therapy in the news

Blogs on Alport syndrome medical therapy

Directions to Hospitals Treating Alport syndrome

Risk calculators and risk factors for Alport syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


As there is no known cure for the condition, treatments are regimented for the symptoms of the condition.


Family members of patients known to have Alport’s syndrome must be screened for symptoms or signs that are consistent with the disease. Genetic counseling must then be made for patients who are also affected by Alport’s syndrome and must be informed of their risk of having offspring with the condition and of their prognosis and progression to end-stage renal disease (ESRD). Family members that are at risk must be screened for hematuria on 2 different occasions. Genetic testing is optional but recommended.[1]



When suspecting a patient has Alport’s syndrome, the following tests are recommended according to expert opinion published in February 2013 by Savige and colleagues in the Journal of American Society of Nephrology (JASN)[1]:

  • Microalbuminuria/proteinuria
  • Audiometry
  • Ophthalmologic exam
  • Renal biopsy (optional)
  • Genetic testing (optional)

Although no cure is available for Alport’s syndrome, patients may benefit from optimizing blood pressure, reducing proteinuria, and delaying renal progression into ESRD and subsequent dialysis and/or transplantation. In addition, multidisciplinary professional approach, including ophthalmologic, genetic, psychosocial, and educational aid is required to improve patients’ quality of life.

Goals of Treatment

Goals of management in Alport's syndrome are summarized as follows[1]:

  • Optimize hypertension
  • Optimize dyslipidemia
  • Reduce degree of proteinuria
  • Reduce hearing loss by preventing environmental exposure

Pharmacologic Therapy

Generally, anti-hypertensive medications and anti-lipidemic medications are used to control blood pressure and dyslipidemia.

Angiotensin-Converting Enzyme Inhibitors

To start ACE-I even before the presence of proteinuria[1]


The use of cyclosporine has been debatable and insufficiently valid. One study with only ___ subjects showed improved outcome.[2]

Matrix Metalloproteinase Inhibitors

MMP inhibitors in mouse models and in early phase seem promising since MMP is upregulated in Alport’s syndrome and contributes to the disease progression and degradation of the GBM.[3]

Protein Restriction

One study in dogs showed that protein restriction delays progression of GBM splitting seen in patients with Alport’s syndrome, suggesting a possible lifestyle intervention for improved survival.[4]

Renal Replacement Therapy


Renal transplantation

Choice of donor must be made carefully only between non-carrier and non-affected family members. Patients with TBMN can be donors only if have normal BP, level of proteinuria, and kidney function and have confirmed genetic and pathological work-up to rule out X-linked Alport’s syndrome.[1] Despite transplantation, there is up to 5% risk of developing anti-GBM disease among males.[1] The risk is higher with subsequent transplantations. If anti-GBM is suspected following transplant with symptoms of renal impairment, allograft biopsy is required.[1] Females usually have better outcome with transplantation. 15% still develop ESRD by 60 years of age. Regular follow-up is recommended.[1]

Future Therapies

Gene therapy and stem cell therapy are currently contemplated to be promising therapeutic options for patients with Alport’s syndrome; but their true value has not yet been in effect because they require further evaluation.[5][6][7]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013). "Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy". J Am Soc Nephrol. 24 (3): 364–75. doi:10.1681/ASN.2012020148. PMID 23349312.
  2. Chen D, Jefferson B, Harvey SJ, Zheng K, Gartley CJ, Jacobs RM; et al. (2003). "Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model". J Am Soc Nephrol. 14 (3): 690–8. PMID 12595505.
  3. Rao VH, Lees GE, Kashtan CE, Nemori R, Singh RK, Meehan DT; et al. (2003). "Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS)". Kidney Int. 63 (5): 1736–48. doi:10.1046/j.1523-1755.2003.00939.x. PMID 12675849.
  4. Valli VE, Baumal R, Thorner P, Jacobs R, Marrano P, Davies C; et al. (1991). "Dietary modification reduces splitting of glomerular basement membranes and delays death due to renal failure in canine X-linked hereditary nephritis". Lab Invest. 65 (1): 67–73. PMID 2072666.
  5. Robinson WF, Huxtable CR, Gooding JP (1985). "Familial nephropathy in cocker spaniels". Aust Vet J. 62 (4): 109–12. PMID 4026716.
  6. Bailey AS, Jiang S, Afentoulis M, Baumann CI, Schroeder DA, Olson SB; et al. (2004). "Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells". Blood. 103 (1): 13–9. doi:10.1182/blood-2003-05-1684. PMID 12958072.
  7. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R; et al. (2001). "Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell". Cell. 105 (3): 369–77. PMID 11348593.

Template:WH Template:WS